🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are increasing worldwide, with data suggesting more than 82 million infections per year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The WHO has listed it as a "critical concern". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This milestone represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Results and Worldwide Availability

According to data released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of cases of the STI. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The research enrolled hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors treating patients have voiced positive views. Having a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is viewed as crucial to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea around the world.